Histopathological studies and animal models have suggested an inflammatory component in the pathomechanism of the CHMP2B associated frontotemporal dementia (FTD-3).
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A B S T R A C T
Histopathological studies and animal models have suggested an inflammatory component in the pathomechanism of the CHMP2B associated frontotemporal dementia (FTD-3).
In this cross-sectional study, serum and cerebrospinal fluid were analyzed for inflammatory markers in CHMP2B mutation carriers.
Serum levels of CCL4 were increased throughout life. Serum levels of IL-15, CXCL10, CCL22 and TNF-α were significantly associated with cognitive decline, suggesting a peripheral inflammatory response to neurodegeneration. CSF levels of sTREM2 appeared to increase more rapidly with age in CHMP2B mutation carriers.
The identification of a peripheral inflammatory response to disease progression supports the involvement of an inflammatory component in FTD-3.
Introduction
Frontotemporal Dementia (FTD) is a neurodegenerative disease characterized by behavioral changes, language impairments and a marked cognitive decline (Rascovsky et al., 2011) . Onset is often earlier than 60 years of age, progression is inevitable, and with no available treatment, life expectancy is reduced (Brodaty et al., 2012; Onyike and Diehl-Schmid, 2013; Vieira, 2013; Bang et al., 2015) . Familial aggregation is present in 40% of cases, often presenting an autosomal dominant pattern of inheritance (Rosso, 2003; Bang et al., 2015) . Pathogenic mutations causing FTD have been identified in a number of genes including MAPT, GRN, C9orf72, VCP, FUS, TARDBP and CHMP2B, the first three of which accounting for half of all familial cases (Rohrer et al., 2009; Paulson and Igo, 2011) .
Several studies have suggested inflammation as a component of the neuropathological process in FTD. With cerebrospinal fluid (CSF) reflecting the pathology in the brain, CSF biomarkers have supported neuroinflammation in FTD. However, different studies have provided inconsistent results, and so far no specific intrathecal inflammatory profile for sporadic or genetic FTD has been established; one early study of presumed sporadic FTD reported elevated CSF levels of TNF-α (Sjögren et al., 2004) , while another study reported decreased CSF levels of IL-12 (Rentzos et al., 2006a) . Smaller studies reported elevated CSF levels of CXCL8 and IL-15 (Galimberti et al., 2006; Rentzos et al., 2006b ). All of these findings were however not replicated in a later study (Galimberti et al., 2015) . Reports of elevated CSF levels of TGF-β and IL-11 (Sjögren et al., 2004; Galimberti, 2008) have not yet been reproduced nor negated, while elevated CSF levels of CCL2 in sporadic FTD have been identified in two studies (Galimberti et al., 2006 (Galimberti et al., , 2015 .
With the identification of genetic FTDs, focus has shifted to genetically homogenous FTD cohorts. As the progranulin protein seems involved in neuroinflammation and microglia activation (Ahmed et al.,
